Apr 22, 2024 8:00am EDT Excision BioTherapeutics Announces Oral Presentation of Preclinical HSV-1 Keratitis Data at CRISPRMED24 Conference on April 24, 2024
Apr 16, 2024 8:00am EDT Excision BioTherapeutics Announces Oral Presentation of HSV-1 Keratitis Data at CRISPRMED24 Conference on April 24 2024
Apr 10, 2024 8:00am EDT Excision BioTherapeutics Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
Oct 25, 2023 8:30am EDT Excision BioTherapeutics Presents Positive Interim Clinical Data from Ongoing Phase 1/2 Trial of EBT-101 for the Treatment of HIV at ESGCT 30th Annual Congress
Oct 19, 2023 7:50am EDT Excision BioTherapeutics Announces Presentation of Interim Clinical Data for EBT-101 in Latent HIV at Upcoming European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress
Aug 17, 2023 7:30am EDT Excision BioTherapeutics Announces Gene Therapy Publication of Pre-Clinical Data Supporting its First-in-Class CRISPR-Based Gene Therapy Candidate Designed to Functionally Cure HIV-1
Jul 20, 2023 7:00am EDT Excision BioTherapeutics Receives FDA Fast Track Designation for EBT-101, a First-in-Class CRISPR-Based Gene Therapy Candidate to Functionally Cure HIV-1
Jun 01, 2023 9:00am EDT Excision BioTherapeutics Appoints Former Pfizer Chairman and CEO Jeffrey B. Kindler to its Board of Directors
Oct 20, 2022 8:00am EDT Excision BioTherapeutics to Host Key Opinion Leader Webinar on HIV and the Ongoing Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure
Sep 29, 2022 7:30am EDT Excision BioTherapeutics Awarded California Institute for Regenerative Medicine (CIRM) Grant to Support Ongoing Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV